 Head and neck cancer is one of the most common malignant tumors in China, accounting for 19.9 to 30.2 of malignant tumors in this country. Approximately 60 to 70 of patients have stage III or IV disease at the time of diagnosis, and the 5-year overall survival is about 30. The local recurrence rate ranges from 50 to 60. The 5-year overall survival for patients treated with multidisciplinary treatment, which is a common treatment method that includes surgery, chemotherapy, radiotherapy, and biotherapy, has recently increased by 5. Further improvements in the treatment effects of head and neck cancer are required. 